| Source: |
| Type: |
| Process through which new blood vessels. Angiogenesis, the process of new blood vessel formation from pre-existing vessels, plays a crucial role in cancer progression and metastasis. Tumors require a blood supply to grow beyond a certain size and to spread to other parts of the body. Vascular Endothelial Growth Factor (VEGF): VEGF is one of the most important pro-angiogenic factors. It stimulates endothelial cell proliferation and migration, leading to the formation of new blood vessels. Many tumors overexpress VEGF, which correlates with poor prognosis. Hypoxia-Inducible Factor (HIF): In response to low oxygen levels (hypoxia), tumors can activate HIF, which in turn promotes the expression of VEGF and other angiogenic factors. This mechanism allows tumors to adapt to their microenvironment and sustain growth. |
| Normal Healthy |
| 3455- | ALA, | Alpha-lipoic acid inhibits proliferation and migration of human vascular endothelial cells through downregulating HSPA12B/VEGF signaling axis |
| - | in-vitro, | Nor, | HUVECs |
| 1078- | And, | Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-361 |
| 1147- | ART/DHA, | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 |
| - | vitro+vivo, | Ovarian, | HO-8910 | - | vitro+vivo, | Nor, | HUVECs |
| 1178- | Ash, | Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor |
| - | in-vitro, | Nor, | HUVECs | - | in-vivo, | NA, | NA |
| 5174- | Ash, | Withaferin A is a potent inhibitor of angiogenesis |
| - | in-vitro, | Nor, | HUVECs |
| 1146- | AsP, | Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms |
| - | in-vivo, | Nor, | NA |
| 5365- | AV, | Aloe Vera Polysaccharides as Therapeutic Agents: Benefits Versus Side Effects in Biomedical Applications |
| - | Review, | Nor, | NA | - | Review, | IBD, | NA | - | Review, | Diabetic, | NA |
| 956- | BBR, | Berberine inhibits HIF-1alpha expression via enhanced proteolysis |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | GC, | SCM1 |
| 5872- | CA, | Nrf2/ARE-Mediated Antioxidant Actions of Pro-Electrophilic Drugs |
| - | Review, | Nor, | NA |
| 954- | CGA, | Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 4764- | CoQ10, | VitE, | Auxiliary effect of trolox on coenzyme Q10 restricts angiogenesis and proliferation of retinoblastoma cells via the ERK/Akt pathway |
| - | in-vitro, | RPE, | Y79 | - | in-vitro, | Nor, | ARPE-19 | - | in-vivo, | NA, | NA |
| 948- | F, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24/HTB-9 | - | in-vitro, | Nor, | HUVECs |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
| 1005- | GI, | Ginger Constituent 6-Shogaol Inhibits Inflammation- and Angiogenesis-Related Cell Functions in Primary Human Endothelial Cells |
| - | vitro+vivo, | Nor, | HUVECs |
| 3267- | Lyco, | Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways |
| - | in-vitro, | Nor, | HUVECs |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 3478- | MF, | One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study |
| - | Trial, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | C2C12 |
| 3259- | PBG, | Propolis and its therapeutic effects on renal diseases: A review |
| - | Review, | Nor, | NA |
| 4939- | PEITC, | Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo |
| - | in-vitro, | Pca, | PC3 | - | ex-vivo, | Nor, | HUVECs |
| 2999- | PL, | Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation |
| - | in-vivo, | Nor, | HUVECs |
| 1729- | SFN, | Discovery and development of sulforaphane as a cancer chemopreventive phytochemical |
| - | Review, | Nor, | NA |
| 3151- | VitC, | Role of Vitamin C in the Function of the Vascular Endothelium |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:49 Cells:% prod#:% Target#:447 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid